National Institutes of Health: Non-alcoholic Fatty Liver Disease trials

The registry lists 22 Non-alcoholic Fatty Liver Disease studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 1 2Phase 2 12Phase 3 3No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesRecruitingNCT05832229Phase 2
• Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)RecruitingNCT03884075Phase 2
• Vitamin E Dosing StudyCompletedNCT04801849Phase 2Results posted
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Losartan for the Treatment of Pediatric NAFLDTerminatedNCT03467217Phase 2Results posted
• Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin ECompletedNCT01792115Phase 2Results posted
• Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in ChildrenCompletedNCT01529268Phase 2/3Results posted
• The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)CompletedNCT01265498Phase 2Results posted
• Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)CompletedNCT00063635Phase 3Results posted
• Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)CompletedNCT00063622Phase 3Results posted
• Treating Nonalcoholic Steatohepatitis (NASH) With MetforminCompletedNCT00063232Phase 2Results posted
• Treating Nonalcoholic Steatohepatitis With PioglitazoneCompletedNCT00062764Phase 2Results posted
• Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver DiseaseCompletedNCT05669677
• Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver DiseaseCompletedNCT02520609
• Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT02363309
• Genetic Studies of Non-Alcoholic Fatty Liver DiseaseTerminatedNCT01629095
• Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese WomenCompletedNCT00862433Phase 1
• Phase I Trial of Silymarin for Chronic Liver DiseasesCompletedNCT00389376Phase 1
• Weight Management in Nonalcoholic SteatohepatitisCompletedNCT00266019Phase 2
• Effect of Omega-3 PUFA Supplementation in NAFLD PatientsCompletedNCT00230113Not applicable
• Iron Depletion Therapy for Type 2 DM and NAFLDCompletedNCT00230087Not applicable
• Treatment of Nonalcoholic Steatohepatitis With PioglitazoneCompletedNCT00013598Phase 2